Eupraxia Pharmaceuticals (EPRX) Expected to Announce Earnings on Wednesday

Key Points

• Eupraxia Pharmaceuticals is set to announce its quarterly earnings on August 6th, expecting to report earnings of ($0.21) per share.
• Analysts currently maintain a consensus rating of "Buy" for Eupraxia Pharmaceuticals, with an average target price of $11.00.
• Royal Bank of Canada increased its stake in Eupraxia Pharmaceuticals by 21.1%, owning approximately 0.96% of the company after the purchase.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is projected to release its earnings data before the market opens on Wednesday, August 6th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.21) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 1.8%

Shares of EPRX traded down $0.10 on Friday, reaching $5.30. 4,758 shares of the company's stock were exchanged, compared to its average volume of 11,620. The business has a 50 day moving average price of $4.79 and a two-hundred day moving average price of $3.97. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $6.20. The stock has a market capitalization of $190.73 million, a P/E ratio of -6.98 and a beta of 1.51.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 26th. They issued a "buy" rating and a $12.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They issued an "overweight" rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, June 16th. They set a "speculative buy" rating on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $11.00.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently raised its stake in Eupraxia Pharmaceuticals stock. Royal Bank of Canada boosted its stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) by 21.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 342,828 shares of the company's stock after buying an additional 59,683 shares during the period. Royal Bank of Canada owned approximately 0.96% of Eupraxia Pharmaceuticals worth $1,125,000 as of its most recent filing with the SEC.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.